B2i Digital

United States Antimony Corporation (NYSE American, NYSE Texas: UAMY) announced that the company will report Financial and Operational Results for its Second Quarter and Six Months Ended June 30, 2025 on August 12, 2025, at 4:15 PM Eastern Time. US Antimony Corporation (USAC) is a B2i Digital Featured Company. The company’s comprehensive investor profile is at: https://lnkd.in/e4zC5F_v. - Link to the Webcast URL: https://lnkd.in/e8w9UMqf - Questions are to be typed and submitted through the online portal, accessed by the Webcast URL link. - Webcast Replay Location: https://lnkd.in/eGMMC7g4 - News Release available at: https://lnkd.in/eRFXGUaE. USAC produces antimony, zeolite, and precious metals from operations in Montana, Idaho, and Mexico. Antimony products serve flame-retardant, battery, ordnance, and specialty-chemical markets, while Bear River Zeolite supports water filtration, environmental remediation, agriculture, animal nutrition, and other industrial applications. For investor inquiries, contact Jonathan Miller, VP Investor Relations, at jmiller@usantimony.com. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted UAMY stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of UAMY or any security, and it is not intended to offer any opinion on UAMY as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://lnkd.in/dngE2d4m.

OceanPal Inc. (NASDAQ: OP) today announced financial results for the six months ended June 30, 2025, including time charter revenues of $6.2 million and fleet utilization of 92.4%. OceanPal Inc. is a B2i Digital Featured Company. See the company’s full profile at: https://lnkd.in/erxMW6H8. Highlights from the six-month report include: - Cash and cash equivalents of $25.8 million as of June 30, 2025, up from $7.2 million at December 31, 2024; total liabilities were $4.1 million. OceanPal Inc. has no debt. - Active fleet management: the Company completed the sales of the vessels Salt Lake City (February 13, 2025) and Protefs (June 12, 2025). Net cash provided by investing activities totaled $21.0 million in the period. - Continued commercial activity: the MR2 tanker Zeze Start is now employed at a daily rate of $19,500 with Abu Dhabi Marine International Chartering Holdings Limited. See the full release at https://lnkd.in/ePJWfWw9 OceanPal is a global provider of shipping transportation services specializing in the ownership and operation of dry bulk vessels and product tankers. The company is engaged in the seaborne transportation of bulk commodities, including iron ore, coal, and grain, as well as refined petroleum products, with a strategic focus on maximizing long-term shareholder value through disciplined chartering strategies. OceanPal is led by an experienced management team, including Robert Perri, Chief Executive Officer and Vasiliki (Vaso) Plousaki, Chief Financial Officer. To learn more about OceanPal Inc., visit https://www.oceanpal.com.For investor inquiries, contact Edward Nebb at enebb@optonline.net. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted OP stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of OP or any security, and it is not intended to offer any opinion on OP as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://lnkd.in/dngE2d4m.

Kolibri (Nasdaq: KGEI, TSX: KEI) Global Energy’s President & CEO, Wolf Regener, recently presented at Renmark’s Virtual Non-Deal Roadshow. This clip highlights a key upcoming catalyst: the testing of the “East Side” acreage with the Forguson well, which represents significant potential upside not yet reflected in the company’s reserve reports. Kolibri Global Energy Inc. is a B2i Digital Featured Company (https://lnkd.in/eVHcxRGp) focused on acquiring and developing energy projects across the United States. For more information, visit https://kolibrienergy.com and follow Kolibri on X, Facebook, and LinkedIn. Insights from the video include: - Near-Term Catalyst: “The Forguson well is the well that we drilled that we’ll be bringing on production sometime in July.” - Untapped Potential: “We have 3000 net acres out here. The east side is classified as contingent... it’s not classified as Proved, Probable, nor Possible reserves yet.” - Major Growth Opportunity: “That could add quite a bit of reserves and additional well locations to our whole project as we go forward.” Click this link to watch the video: https://lnkd.in/gMm3E23r Led by Wolf Regener, President and CEO, Kolibri Global Energy is focused on unlocking shareholder value through the efficient development of its oil-rich Caney acreage in Oklahoma. The company’s highly experienced management team includes Gary Johnson, CPA, MBA, CFO; Dan Simpson, Director of Engineering; Allan Hemmy, Senior Geologist; and Dalia Isaac, Landman. For additional details, please visit Kolibri’s website at: https://kolibrienergy.com Disclosure: The management of B2i Digital owns shares of unrestricted KGEI stock, purchased in the open market, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of KGEI or any security, and it is not intended to offer any opinion on KGEI as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of [https://lnkd.in/eaTZamhk).

Vycor Medical, Inc. (OTCQB: VYCO) announced financial results for the three and six months ended June 30, 2025, including second-quarter revenue of $496,353, up 22% year over year. Vycor Medical, Inc. is a B2i Digital Featured Venture Company. See the complete profile at https://lnkd.in/eZxxWBVU. Highlights from the quarter include: - VBAS division momentum: Vycor Medical (VBAS) revenue rose 24% in Q2 to $481,788 and 28% for the six-month period to $900,308, with growth led by international markets. - Profitability in the quarter: GAAP operating profit of $51,146 and GAAP net income of $23,887 in Q2; non-GAAP operating profit of $84,481 in Q2 and $106,944 for the six-month period.  - Commercial expansion: new distribution agreements signed for France and Spain to support international growth. - Clinical validation: two additional peer-reviewed papers referencing VBAS were published in Q2, bringing the total to 48; a new study of NovaVision’s NeuroEyeCoach reported meaningful improvements for both home-based and clinic-based use with no significant difference between settings. See Vycor’s press release: https://lnkd.in/gZ-m9zin Vycor operates two divisions: Vycor Medical (ViewSite™ Brain Access System for neurosurgery) and NovaVision (vision rehabilitation therapies for stroke/brain injury patients). To learn more, watch a video replay of Vycor Medical’s recent presentation at the Life Sciences Virtual Investor Forum, featuring CEO Peter Zachariou and President David Cantor, available at this link: https://lnkd.in/eGRR7mdZ. Vycor Medical is led by CEO Peter Zachariou, President David Cantor, and CFO Adrian Liddell, each bringing extensive experience in medical technology, business development, and finance. Learn more about Vycor Medical at https://lnkd.in/eSATjP_X. For investor inquiries, please contact info@vycormedical.com. Disclosure: Management of B2i Digital owns shares of VYCO stock purchased in the open market. This post is not intended to solicit the sale of VYCO or any security, and it is not intended to offer any opinion on VYCO as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclaimer in the Risks and Disclosures section of https://lnkd.in/d3m_BMKB.

Intelligent Bio Solutions (Nasdaq: INBS) announced preliminary fiscal fourth quarter revenue with double-digit sequential and year-over-year growth, as well as strong operational momentum. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a B2i Digital Featured company. View INBS’s comprehensive profile at https://lnkd.in/gCF9hkFm. The company is advancing efforts to secure U.S. FDA 510(k) clearance for its opiate test system while expanding global operations through multilingual system upgrades and localized market engagement. INBS says it expects to report fiscal fourth quarter 2025 revenue increases of approximately 16% sequentially and year-over-year, reflecting continued demand for its higher-margin cartridge sales and steady account growth. Preliminary results indicate sequential revenue growth over both the fiscal third and second quarters. Harry Simeonidis, President & CEO of Intelligent Bio Solutions, stated: “Fiscal 2025 represented a year of disciplined execution and strategic investment. For the fiscal fourth quarter, we expect to report another quarter of sequential and year-over-year revenue growth. In addition to our strong revenue performance, during the quarter we also made significant progress on the regulatory pathway in seeking U.S. FDA 510(k) clearance and continued scaling our operations globally with system upgrades and localization.” Operational Highlights, noted in the news release: - Submitted updated FDA 510(k) application for its opiate test system for codeine, supported by new scientific and clinical validation data. - Completed multilingual upgrades to the Intelligent Fingerprinting Drug Screening System, supporting broader global adoption. - Launched localized websites and enhanced CRM workflows to improve partner and end-user engagement across Europe, the Middle East, and Latin America. Please read the full news release at this link: https://lnkd.in/eQck8kvh. Note that the preliminary unaudited revenue results for the fiscal fourth quarter and full year ended June 30, 2025, are based on information available to management as of the date of today’s press release and are, therefore, subject to adjustments based on the company’s completion of its year-end financial close process. The company expects to disclose financial results for the fiscal fourth quarter and fiscal year ended June 30, 2025, in its upcoming Annual Report on Form 10-K, scheduled to be filed with the Securities and Exchange Commission during the week commencing August 11, 2025. For investor inquiries, visit https://investors.ibs.inc or contact Valter Pinto at INBS@kcsa.com, KCSA Strategic Communications.

Kolibri Global Energy Inc. (Nasdaq: KGEI, TSX: KEI) announced strong production results from its Lovina wells in Oklahoma’s Tishomingo field, with wells producing higher oil percentages than previously drilled wells and showing promising flow rates during cleanup. Kolibri Global Energy Inc. is a B2i Digital Featured Company. View their complete profile at https://lnkd.in/eVHcxRGp and follow Kolibri on X, Facebook, and LinkedIn. Highlights of today’s operations update include: - Lovina Wells (100% working interest), averaging 571, 643, 416, and 322 BOEPD, respectively, all with ~81-84% oil content during flowback, exceeding historical oil percentages. - Production tubing installation beginning next week is expected to boost production rates based on offset well performance. - Forguson Well (46% working interest) successfully fracture stimulated, testing economics of 3,000 acres on eastern acreage not included in reserves. - Barnes Wells drilling to commence August 11, 2025, targeting 1.5-mile laterals with 99.9% working interest. - Higher oil percentages are expected to improve netbacks and reduce decline rates. Wolf Regener, President and CEO, commented, “We are thrilled about the high oil percentage of the Lovina wells, which we believe generally leads to higher netbacks for the Company and will lead to slower decline rates. We are also looking forward to seeing what the ultimate productivity of these wells will be. The east side acreage, where the Forguson well is located and Kolibri has approximately 3,000 net acres, is not included in the December 31, 2024, reserve report. The Caney target for the Forguson well has very similar characteristics and thickness to the main part of the field in Kolibri’s proved acreage, except that it is shallower. If the Forguson well proves to be economic, in addition to adding cash flow, it could lead to many additional development locations for the Company. We are looking forward to the additional production and cash flow from all of these wells, which we expect will significantly increase the Company’s cash flow and add incremental value to our shareholders.” See the full news release at: https://lnkd.in/eQ8Gv5wa Kolibri is led by Wolf Regener, President and CEO, alongside a seasoned technical team including CFO Gary Johnson, CPA, MBA, Director of Engineering Dan Simpson, Senior Geologist Allan Hemmy, and Landman Dalia Isaac. The company is focused on developing its oil-rich Caney acreage in Oklahoma. For additional details, please visit Kolibri’s website at: https://kolibrienergy.com.

Xtant Medical Holdings (NYSE‑American: XTNT), a B2i Digital Featured Company specializing in surgical spine, orthopedic, and woundcare solutions, will report its Q2 2025 financial results on Tuesday, August 12, 2025, before market open. A conference call featuring President & CEO Sean Browne and CFO Scott Neils is scheduled for 8:30 AM Eastern Time, with both phone dial-in and webcast access. Replay will be made available via Xtant’s investor website afterward. The company’s vertically-integrated biologics platform and recent product innovations position it for growth, with further detail to follow at the release. https://lnkd.in/e9TwXp_q The company is led by Chief Executive Officer Sean Browne, Chief Financial Officer Scott Neils, and Chief Operating Officer Mark Schallenberger, whose collective experience spans medical-device commercialization, corporate finance, and orthobiologologic innovation. For more information, visit https://lnkd.in/etF3qHWF. Investor inquiries: Kevin Gardner at LifeSciences Advisors, KGardner@lifesciadvisors.com. Disclosure: The management of B2i Digital may purchase shares of unrestricted XTNT stock in the open market, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the purchase or sale of XTNT or any security, nor does it offer any investment opinion. Conduct your own research and consult professional advisers before making investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/

OS Therapies (NYSE-A: OSTX) announced that the company held a successful Scientific Advice Meeting with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in July and submitted an Innovative Licensing and Access Pathway (ILAP) application to advance regulatory approval for OST-HER2 in preventing or delaying recurrent, fully resected, pulmonary metastatic osteosarcoma. OS Therapies is a B2i Digital Featured Company. View their comprehensive profile at https://lnkd.in/epFNRZQB. The MHRA recommended applying for Project Orbis when submitting for regulatory approval to align the UK’s Marketing Authorization Application process with the US FDA’s Biologics Licensing Application (BLA) Accelerated Approval Program. Project Orbis is an FDA-led global initiative that enables simultaneous submission and review of oncology products across multiple countries, potentially accelerating patient access to promising cancer treatments. Highlights from today’s news release include: - Positive feedback received from the UK MHRA Scientific Advice Meeting held in July 2025. - ILAP application submitted to begin UK regulatory approval process for OST-HER2. - European Medicines Agency rapporteur meeting scheduled for October 2025 to initiate EU-wide Marketing Authorization via the Centralized Procedure. Paul Romness, MPH, CEO of OS Therapies, remarked, “We are pleased with the outcome of our meeting with MHRA in the UK and are working to ensure that we provide FDA and MHRA everything they need to be able to rapidly approve OST-HER2 for metastatic osteosarcoma patients. We have officially begun the regulatory process in Europe as the next part of our regulatory strategy to bring this novel immunotherapy to osteosarcoma patients worldwide.” Read the full release at: https://lnkd.in/eRykkmFG Led by CEO Paul Romness and an experienced executive team that includes Christopher Acevedo (CFO), Robert Petit (Chief Medical and Scientific Officer), John Doll (Chief of Staff), and Gerald Commissiong (Chief Business Officer), OS Therapies is focused on driving its pipeline forward to deliver potentially transformative treatments for osteosarcoma and other hard-to-treat cancers. Learn more about OS Therapies’ work at https://lnkd.in/eaAJSfqz and visit B2i Digital for updates. For investor-related questions, please see OS Therapies’ Investor Relations page or email OSTX@waterseid.com. Disclosure: The management of B2i Digital owns unrestricted shares of OSTX stock purchased in the open market. This post is not intended to solicit the sale of OSTX or any security, and it is not intended to offer any opinion on OSTX as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclosure in the Risks and Disclosures section of https://lnkd.in/epFNRZQB

OS Therapies (NYSE-A: OSTX) reported statistically significant positive 2-year overall survival results from an interim analysis of its Phase 2b trial of its off-the-shelf immunotherapy candidate OST-HER2 for preventing or delaying recurrent, fully resected, pulmonary metastatic osteosarcoma. OS Therapies is a B2i Digital Featured Company. View their comprehensive profile at https://lnkd.in/epFNRZQB. The company also announced its NYSE American listing has been added to the Russell Microcap, Russell Microcap Value, and Russell Microcap Growth indexes. FTSE Russell determines membership for its Russell indexes based on objective, market-capitalization rankings, and style attributes. Investment managers and institutional investors widely use Russell indexes for index funds and as benchmarks for active investment strategies. Highlights from today’s news release include: - 66.6% of patients treated with OST-HER2 (18/27) reached 2-year overall survival versus 40% in historical controls (p = 0.0046). - The FDA issued a Biologics License Application (BLA) number for OST-HER2 ahead of the anticipated filing following the pending August 27, 2025, End of Phase 2 Meeting. - The company is working with the FDA to align metrics for Regenerative Medicine Advanced Therapy (RMAT) designation, Breakthrough Therapy Designation (BTD), and BLA through the Accelerated Approval pathway. Paul Romness, MPH, Chairman & CEO of OS Therapies, remarked, “We are seeking to bring this novel immunotherapy to market to improve the survival rates in pulmonary metastatic osteosarcoma, and today’s updated interim overall survival data continues to show a statistically significant benefit for OST-HER2-treated patients compared with control. We believe that continued statistically significant outperformance in overall survival of OST-HER2 treated patients compared with historical control, together with the statistically significant positive 12-month Event Free Survival data presented at MIB Factor in June 2025, will provide the necessary scientific and medical basis to support a BLA under the FDA’s Accelerated Approval Program.” Read the full release at: https://lnkd.in/ek2Hwt5A Led by CEO Paul Romness and an experienced executive team that includes Christopher Acevedo (CFO), Robert Petit (Chief Medical and Scientific Officer), John Doll (Chief of Staff), and Gerald Commissiong (Chief Business Officer), OS Therapies is focused on driving its pipeline forward to deliver potentially transformative treatments for osteosarcoma and other hard-to-treat cancers. Learn more about OS Therapies’ work at https://lnkd.in/eaAJSfqz and visit B2i Digital for updates. For investor-related questions, please see OS Therapies’ Investor Relations page or email OSTX@waterseid.com.

Intelligent Bio Solutions (Nasdaq: INBS) has submitted comprehensive Additional Information to the FDA, strengthening its 510(k) package and supporting the clearance process for its fingerprint sweat-based drug screening system. This updated submission features extensive new data supporting the platform’s security and performance, positioning the company for its anticipated U.S. market entry in 2025. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a B2i Digital Featured company. View INBS’s comprehensive profile at https://lnkd.in/gCF9hkFm. Over 10,000 hours were dedicated to compiling the data for the company’s updated submission. INBS conducted rigorous cybersecurity assessments, including penetration testing and electromagnetic compatibility testing, confirming the system’s reliability in diverse operating conditions. The comprehensive package delivered to the FDA contained 23 technical reports with over 100 supporting documents, 1,900 pages and 7,800+ lines of data. Harry Simeonidis, President & CEO of Intelligent Bio Solutions, stated: “Securing FDA clearance has been a top priority as we look to bring our fingerprint sweat-based solution to more markets, particularly those with significant commercial potential, such as the multi-billion-dollar U.S. market. The data we have gathered reflects the outstanding work of our R&D team, whose technical expertise has strengthened the case for our technology’s accuracy and reliability.” Please read the full news release at this link: https://lnkd.in/e5H6EiXp Led by CEO Harry Simeonidis and CFO Spiro Sakiris, INBS is advancing hygienic, rapid, and cost-effective fingerprint sweat-based testing worldwide. The company’s non-invasive, patented technology delivers results in under ten minutes and now supports more than 450 accounts across 24 countries in the workplace safety, law enforcement, drug treatment, and forensics markets. Its experienced global management team includes Anna Turkington, Ghanshyam Poudel, Taylor Doherty, Daniel Brown, Doug Heath, Sugam Pokharel, Victoria Gavrilenko, Rafael da Luz, MBA, Callistus Sequeira, Derek Mapoli MBus, and Peter Passaris. For investor inquiries, visit https://investors.ibs.inc or contact Valter Pinto at INBS@kcsa.com, KCSA Strategic Communications.